PSB-CB5

CAS No. 1627710-30-8

PSB-CB5( —— )

Catalog No. M34207 CAS No. 1627710-30-8

PSB-CB5 (GPR18-IN-32)2 is a GRP18 antagonist with anti-inflammatory activity and can be used to study obesity and metabolic disorders.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 123 Get Quote
5MG 183 Get Quote
10MG 310 Get Quote
25MG 502 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PSB-CB5
  • Note
    Research use only, not for human use.
  • Brief Description
    PSB-CB5 (GPR18-IN-32)2 is a GRP18 antagonist with anti-inflammatory activity and can be used to study obesity and metabolic disorders.
  • Description
    PSB-CB5 is a potent and selective antagonist of GRP18. PSB-CB5 has the potential for the research of metabolic disease and obesity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    GPR
  • Recptor
    GPR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1627710-30-8
  • Formula Weight
    384.88
  • Molecular Formula
    C20H17ClN2O2S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C\1N2C(=N/C1=C\C3=CC(OCC4=CC=C(Cl)C=C4)=CC=C3)SCCC2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kotańska M, et al. Effects of GPR18 Ligands on Body Weight and Metabolic Parameters in a Female Rat Model of Excessive Eating. Pharmaceuticals (Basel). 2021;14(3):270.?
molnova catalog
related products
  • FTBMT

    FTBMT is a selective GPR52 agonist (EC50: 75 nM) and it also has antipsychotic and procognitive properties.

  • MK 1903

    MK 1903 is a potent and selective complete agonist for the hydroxy-carboxylic acid receptor 2 (HCA2). HCA2 is also known as G protein-coupled receptor 109A(GPR109A).

  • ML 145

    ML 145 is a selective and potent antagonist of human GPR35, with no significant activity against GPR35 in any of its immediate rodent homologs.